Safety and efficacy of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta‐analysis
Obesity Reviews · 2024-11 · 25 (11)
DOI: 10.1111/obr.13811 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Obesity Reviews, online erschienen am 12.08.2024. Verfasst von Ali Esparham und 4 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Bariatric Surgery, Liraglutide, Weight Gain, Weight Loss. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
Introduction
Weight regain and insufficient weight loss are major challenges after metabolic bariatric surgery (MBS), affecting patients' comorbidities and quality of life. The current systematic review and meta‐analysis aim to assess the efficacy and safety of GLP‐1 receptor agonists (GLP‐1 RA) in patients with weight regain or insufficient weight loss after MBS.
Methods
A systematic search was conducted across PubMed, Embase, Scopus, and Web of Science databases to find the relevant studies.
Results
A total of 19 articles were included. The highest doses of liraglutide and semaglutide were 3 mg per day and 1 mg once weekly, respectively, in the included studies. The mean differences in weight and body mass index after treatment were −7.02 kg or 3.07 kg/m 2 , −8.65 or −5.22 kg/m 2 , and −6.99 kg or −3.09 kg/m 2 for treatment durations of ≤ 6 months, 6–12 months, and >12 months with liraglutide, respectively. Additionally, weekly semaglutide showed significantly greater weight loss compared to daily liraglutide, with a mean difference of 4.15 kg. Common complications included nausea (19.1%), constipation (8.6%), abdominal pain (3.7%), and vomiting (2.4%).
Conclusion
Using GLP‐1 RA is a safe and effective treatment for weight regain and insufficient weight loss after MBS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Endoscopic and Minimally Invasive Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of General Surgery, School of Medicine, Surgical Oncology Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Internal Medicine, University of Oklahoma School of Community Medicine, Tulsa, Oklahoma, USA.
- Department of Surgery, University of Oklahoma, School of Community Medicine, Tulsa, Oklahoma, USA.
- Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
ORCID-Profile: Zhamak Khorgami
Zitieren
APA
Esparham, A., Mehri, A., Dalili, A., Richards, J., & Khorgami, Z. (2024). Safety and efficacy of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta‐analysis. Obesity Reviews, 25(11). https://doi.org/10.1111/obr.13811
Vancouver
Esparham A, Mehri A, Dalili A, Richards J, Khorgami Z. Safety and efficacy of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta‐analysis. Obesity Reviews. 2024;25(11). doi:10.1111/obr.13811
BibTeX
@article{Esparham2024,
author = {Esparham, Ali and Mehri, Ali and Dalili, Amin and Richards, Jesse and Khorgami, Zhamak},
title = {Safety and efficacy of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta‐analysis},
journal = {Obesity Reviews},
year = {2024},
volume = {25},
number = {11},
doi = {10.1111/obr.13811}
}
EUVIMED